Skip to contentC
China Pharma Holdings, Inc.
C
CPHIChina Pharma Holdings, Inc. Q3 2015 · 10-Q
Revenue$4.48M$4.48M−19.5% vs Q3 2014 Net Income$2.93M$2.93MN/M vs Q3 2014 EPS Diluted$0.07$0.07N/M vs Q3 2014 Gross Profit$322,000−78.7% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
China Pharma Holdings, Inc. · CIK 1106644 · Engraved from SEC EDGAR
Operating Cash Flowderived$1,167,687+539.4% Free Cash Flowderived$1,167,687N/M Margins · derivedGross margin7.2%−19.9 pt vs Q3 2014
Operating margin71.3%+178.9 pt vs Q3 2014
Net margin65.5%+179.1 pt vs Q3 2014
ended Sep 30, 2015 · filed Nov 16, 2015 · 47 d after period end